Karyopharm reports fourth quarter and full year 2023 financial results and highlights recent company progress

–  total revenue of $146 million and u.s. xpovio® (selinexor) net product revenue of $112 million for full year 2023, meeting company's guidance – – top-line data readouts from three pivotal phase 3 trials evaluating selinexor in endometrial cancer, myelofibrosis and multiple myeloma expected in 2025 –  –  company provides full-year 2024 total revenue guidance of $140 million to $160 million, including u.s. xpovio net product revenue guidance of $100 million to $120 million ; cash runway to late 2025 –   –  conference call scheduled for today at 8:00 a.m. et — newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking